ABT-202

Summary

ABT-202 is a drug developed by Abbott, which acts as an agonist at neural nicotinic acetylcholine receptors and has been researched for use as an analgesic, although it has not passed clinical trials.[1][2][3]

ABT-202
Identifiers
  • (R)-1-(Pyridin-3-yl)pyrrolidin-3-amine
CAS Number
  • 309959-34-0 ☒N
PubChem CID
  • 39220800
ChemSpider
  • 16397614 checkY
UNII
  • RJ89CX560B
Chemical and physical data
FormulaC9H13N3
Molar mass163.224 g·mol−1
3D model (JSmol)
  • Interactive image
  • N[C@@H]1CCN(C2=CC=CN=C2)C1
  • InChI=1S/C9H13N3/c10-8-3-5-12(7-8)9-2-1-4-11-6-9/h1-2,4,6,8H,3,5,7,10H2/t8-/m1/s1 ☒N
  • Key:LVGMMVAWLISWJD-MRVPVSSYSA-N ☒N
 ☒NcheckY (what is this?)  (verify)

References edit

  1. ^ Jain KK (January 2004). "Modulators of nicotinic acetylcholine receptors as analgesics". Current Opinion in Investigational Drugs. 5 (1): 76–81. PMID 14983978.
  2. ^ Romanelli MN, Gratteri P, Guandalini L, Martini E, Bonaccini C, Gualtieri F (June 2007). "Central nicotinic receptors: structure, function, ligands, and therapeutic potential". ChemMedChem. 2 (6): 746–67. doi:10.1002/cmdc.200600207. PMID 17295372. S2CID 34763474.
  3. ^ Xu N, Kim GE, Gregg H, Wagdy A, Swaine BA, Chang MS, El-Shourbagy TA (September 2004). "Automated 96-well liquid-liquid back extraction liquid chromatography-tandem mass spectrometry method for the determination of ABT-202 in human plasma". Journal of Pharmaceutical and Biomedical Analysis. 36 (1): 189–95. doi:10.1016/j.jpba.2004.05.013. PMID 15351065.